SCHEMBL332862

SCHEMBL332862

Cn1nccc1-c1ccc(Sc2cc(F)cc(C3(C(N)=O)CCOCC3)c2)cc1

nearest known ligand 0.78

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 10/20 0.78
AKT1 P31749 2/20 0.38
CD274 Q9NZQ7 1/20 0.36
PIK3CD O00329 1/20 0.35
MMP1 P03956 1/20 0.34
MMP13 P45452 1/20 0.34
AKT2 P31751 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
P2RX7 Q99572 1/20 0.33
CYP11B2 P19099 1/20 0.33
ABL1 P00519 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332390 0.89 ALOX5 (0.61) ALOX5AKT1CD274MMP1MMP13
SCHEMBL332120 0.89 ALOX5 (0.61) ALOX5AKT1CD274AKT2JAK1
Pf-4191834 SCHEMBL29369341 0.86 ALOX5 (0.81) ALOX5AKT1CD274PIK3CDJAK1
Pf-4191834 SCHEMBL332973 0.86 ALOX5 (0.81) ALOX5AKT1CD274PIK3CDJAK1
SCHEMBL332240 0.84 ALOX5 (0.76) ALOX5AKT1CD274PIK3CDAKT2
SCHEMBL332324 0.83 ALOX5 (0.66) ALOX5AKT1CD274PIK3CDAKT2
SCHEMBL332424 0.79 ALOX5 (0.62) ALOX5AKT1PIK3CDAKT2HRH3
SCHEMBL332537 0.79 ALOX5 (0.74) ALOX5AKT1CD274PIK3CDHRH3
SCHEMBL8179150 0.79 ALOX5 (0.77) ALOX5MMP1MMP13
SCHEMBL15803498 0.78 ALOX5 (0.68) ALOX5AKT1CD274PIK3CDJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097733-B2 Pyrazole derivatives as 5-LO-inhibitors PFIZER INC. (US) 2012-01-17 US disclosed
US-8097733-B2 Pyrazole derivatives as 5-LO-inhibitors PFIZER INC. (US) 2012-01-17 US disclosed
US-8097733-B2 Pyrazole derivatives as 5-LO-inhibitors PFIZER INC. (US) 2012-01-17 US disclosed
EP-2225229-A1 PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS Pfizer Inc. (US) 2010-09-08 EP disclosed
US-20090227634-A1 Pyrazole Derivatives as 5-LO-Inhibitors PFIZER INC. 2009-09-10 US disclosed
US-20090227634-A1 Pyrazole Derivatives as 5-LO-Inhibitors PFIZER INC. 2009-09-10 US disclosed
US-20090227634-A1 Pyrazole Derivatives as 5-LO-Inhibitors PFIZER INC. 2009-09-10 US disclosed
WO-2009069044-A1 PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS PFIZER INC. (US) 2009-06-04 WO disclosed
WO-2009069044-A1 PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS PFIZER INC. (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227634-A1 Pyrazole Derivatives as 5-LO-Inhibitors ALOX5, ALOX15, CYP3A5 ALOX5 1/4885AKT1 3057/4885CD274 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.